• Syringin Targets EGFR/PI3K/Akt in Renal Cell Carcinoma

  2026-08-11

  A 2024 study identifies syringin as a potential renal cell carcinoma treatment component that suppresses malignant phenotypes and increases sunitinib sensitivity. By integrating network pharmacology, molecular docking, bioinformatics, cellular assays, and western blotting, the authors associate these effects with inhibition of the EGFR/PI3K/Akt pathway.

• Tricine-SDS-PAGE Gel Preparation Kit Guide

  2026-08-11

  The Tricine-SDS-PAGE Gel Preparation Kit is intended for higher-resolution protein electrophoresis and peptide separation in the low-kilodalton range, where conventional Tris-glycine SDS-PAGE may provide limited separation. It is suitable for denaturing or non-denaturing research workflows when configured appropriately, but it is not intended for diagnostic or medical use.

• DiscoveryProbe Protease Inhibitor Library Guide

  2026-08-10

  The DiscoveryProbe Protease Inhibitor Library turns 825 pre-dissolved compounds into an automation-ready platform for protease inhibition, apoptosis assay development, and phenotype-first screening. This guide connects biochemical kinetics with high-content imaging while using the DdmDE defense study to sharpen target-engagement and time-resolved assay design.

• (S)-(+)-Ibuprofen COX Inhibitor Workflows

  2026-08-09

  Build cleaner inflammation assays with an enantiopure COX inhibitor, from solvent-compatible stock preparation to orthogonal prostaglandin and viability readouts. The same workflow can be extended cautiously into environmental toxicology, where ibuprofen concentration, persistence, and stereochemistry affect interpretation.

• Aging, Mitochondrial ROS, and Macrophage Phagocytosis

  2026-08-08

  The reference study identifies a mechanistic link between aging, mitochondrial reactive oxygen species, collagen overproduction, and defective macrophage phagocytosis. Its experiments suggest that collagen-mediated disruption of F-actin dynamics is a targetable downstream process, while MitoTEMPO partially restores bacterial uptake in aged macrophages.

• Fe3O4@ZIF-8 for Jaw Osteomyelitis: Dual Action

  2026-08-07

  The reference study presents Fe3O4@ZIF-8 core–shell nanoparticles as a platform that combines pH-responsive antibacterial activity with magnetic-field-assisted bone regeneration. Its central contribution is to address the coupled problems of persistent infection and bone loss in jaw osteomyelitis through Zn2+ release, bacterial stress sensitization, and Fe3O4-mediated osteogenic support.

• Phosbind Acrylamide: Elevating Protein Phosphorylation Analy

  2026-08-07

  Phos binding reagent (Phosbind) acrylamide streamlines phosphorylation detection in SDS-PAGE, enabling clear discrimination between phosphorylated and non-phosphorylated proteins—without the need for phospho-specific antibodies. Its robust workflow integration and antibody-free detection uniquely position it for advanced signal transduction and kinase activity research.

• 2'3'-cGAMP (Sodium Salt): Unraveling STING Pathway Resistanc

  2026-08-06

  Explore how 2'3'-cGAMP (sodium salt) illuminates STING-mediated innate immune response resistance, with new insights for immunotherapy research and radiotherapy enhancement. Discover groundbreaking findings and practical protocol guidance.

• Direct Programming of Fibroblasts to Thymic Epithelium via F

  2026-08-06

  This study elucidates the mechanisms by which overexpression of FOXN1 directly reprograms mouse embryonic fibroblasts into thymic epithelial-like cells (iTECs), providing a foundational in vitro system for studying thymic function and T cell development. Key findings reveal the role of Notch signaling inhibition in mTEC differentiation and highlight actionable molecular checkpoints for improving iTEC maturation, advancing both basic immunology and translational regenerative research.

• Dihydrotestosterone in Research: Applied Workflows and Troub

  2026-08-05

  Harness the power of Dihydrotestosterone (DHT) to dissect androgen receptor signaling and model disease-relevant pathways. This article delivers actionable experimental protocols, advanced use-cases, and real-world troubleshooting strategies, enabling researchers to maximize assay reproducibility and translational impact.

• Hepatic Uptake of PEGylated Iron Oxide Nanoparticles: Cellul

  2026-08-05

  This study systematically dissects how PEG chain length and nanoparticle size dictate hepatic uptake patterns in vivo and in vitro, revealing unexpected cell-type preferences. The findings provide critical design guidance for nanomedicines seeking to minimize off-target liver accumulation.

• FAISL lncRNA Blocks FAK Cleavage to Drive TNBC Metastasis

  2026-08-04

  The reference study uncovers how FAISL, a long noncoding RNA, directly binds and protects FAK from Calpain 2-mediated proteolysis, promoting triple negative breast cancer (TNBC) progression and metastasis. This mechanism highlights a novel regulatory axis in TNBC and points to FAISL as a promising therapeutic target for aggressive breast cancer.

• AM 281 in Neuroglial Modulation: Unveiling CB1 Antagonism’s

  2026-08-04

  Explore the unique neuroglial mechanisms of AM 281, a potent CB1 cannabinoid receptor antagonist. This in-depth article reveals how AM 281 advances memory impairment research and offers new insights into the CB1-CREB-GLT-1 pathway for neuropharmacology.

• FPH1 (BRD-6125) Streamlines Hepatocyte Proliferation Assays

  2026-08-03

  FPH1 (BRD-6125) transforms the scalability and reproducibility of human hepatocyte cultures, enabling donor-independent expansion and enhanced functional maturation. This article details optimized workflows, troubleshooting strategies, and how FPH1’s integration supports cutting-edge gene therapy and optogenetic research.

• GI 254023X: Reliable ADAM10 Inhibitor for Assay Reproducibil

  2026-08-03

  This article addresses real-world laboratory challenges in cell viability, cytotoxicity, and signaling assays, demonstrating how GI 254023X (SKU A4436) from APExBIO provides reproducible, data-driven solutions. Scenario-based Q&As dissect best practices for experimental design, protocol optimization, and vendor selection, maximizing the reliability and translational value of ADAM10 inhibition workflows.

8580 records 9/572 page Previous Next First page 上5页 678910 下5页 Last page